UNSPSC 51314306: Cetirizine/pseudoephedrine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE501. This VA Drug Class (RE501) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT.

UNSPSC 51314306 Cetirizine/pseudoephedrine is a Commodity code nominally covering antihistamine-decongestant pharmaceutical products, but the recent state and local opportunities tagged to this code show minimal alignment with the code's stated scope. The three most recent solicitations involve naloxone procurement, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and OTC products — none of which center on cetirizine/pseudoephedrine specifically. The mismatch suggests either broad tagging practices by state and local procurement offices or that this code is underutilized for its nominal product category. State and local issuing bodies posting under this code include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and cooperative purchasing alliances serving multistate government facilities (Minnesota MMCAP). The issuing-body mix spans single counties, state agencies, and regional cooperative purchasing vehicles, though the sample is too small to characterize repeat buyers or dominant procurement patterns.

The three recent opportunities reflect activity in Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, with bids due July 26, 2023 (note: the due date appears inconsistent with the posting date and is likely a data error in the source). The Texas HHS Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a direct-to-manufacturer pharmacy benefit program — an exploratory information-gathering solicitation rather than a competitive bid. The Minnesota MMCAP issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products across multistate members, with proposals due March 26, 2026 and contract awards effective July 1, 2026. The code shows little relevant recent activity specifically tied to cetirizine/pseudoephedrine procurement.